Skip to main content

Table 1 Baseline clinical characteristics

From: Influence of preprocedural glycemic control on clinical outcomes of endovascular therapy in diabetic patients with lower extremity artery disease: an analysis from a Korean multicenter retrospective registry cohort

 

Total (n = 1103)

HbA1c < 7.0 (n = 432)

HbA1c ≥ 7.0 (n = 671)

p

Age (years)

68.2 ± 8.9

69.4 ± 8.9

67.5 ± 8.7

0.001

Old age (≥ 80 years)

96 (8.7%)

48 (11.1%)

48 (7.2%)

0.028

Male

897 (81.3%)

365 (84.5%)

532 (79.3%)

0.033

Hemoglobin A1c (%)

7.6 ± 1.6

6.3 ± 0.5

8.5 ± 1.4

< 0.001

BMI (kg/m2)

24.1 ± 3.8

24.0 ± 3.9

24.2 ± 3.7

0.607

Low BMI (< 18.5 kg/m2)

46 (4.4%)

19 (4.7%)

27 (4.2%)

0.757

Hypertension

870 (78.9%)

347 (80.3%)

523 (77.9%)

0.365

Use of Insulin

361 (32.7%)

109 (25.2%)

252 (37.6%)

< 0.001

Hypercholesterolemia

426 (38.6%)

176 (40.7%)

250 (37.3%)

0.255

Current smoker

288 (26.1%)

101 (23.4%)

187 (27.9%)

0.106

Chronic kidney disease

279 (25.3%)

124 (28.7%)

155 (23.1%)

0.040

End-stage renal disease

166 (15.0%)

72 (16.7%)

94 (14.0%)

0.262

Coronary artery disease

653 (59.2%)

263 (60.9%)

390 (58.1%)

0.380

Congestive heart failure

57 (5.2%)

30 (6.9%)

27 (4.0%)

0.037

Previous history of stroke

185 (16.8%)

81 (18.8%)

104 (15.5%)

0.161

Previous history of EVT

99 (9.0%)

46 (10.6%)

53 (7.9%)

0.131

Previous history of bypass surgery

28 (2.5%)

10 (2.3%)

18 (2.7%)

0.845

Previous history of amputation

81 (7.3%)

33 (7.6%)

48 (7.2%)

0.813

Rutherford classification

   

0.201

 1

89 (8.1%)

40 (9.3%)

49 (7.3%)

 

 2

259 (23.5%)

106 (24.5%)

153 (22.8%)

 

 3

272 (24.7%)

106 (24.5%)

166 (24.7%)

 

 4

80 (7.3%)

33 (7.6%)

47 (7.0%)

 

 5

236 (21.4%)

80 (18.5%)

156 (23.2%)

 

 6

167 (15.1%)

67 (15.5%)

100 (14.9%)

 
  1. Values are presented as mean ± standard deviation or number (%) unless otherwise stated
  2. BMI body mass index, EVT endovascular therapy